Madrigal Pharmaceuticals, Inc. MDGL R2K

Healthcare · Biotechnology · United States

https://www.madrigalpharma.com

Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.

Market & Price

Market Cap

$11.46B

Current Price

$497.27

High / Low (52W)

$602.83 / $272.67

Beta

-1.04

Valuation

Stock P/E

Industry PE

23.65

Forward P/E

40.17

PEG Ratio

Book Value

$23.59

Price to Book

21.08

P/S

10.12

EV/EBITDA

-35.26

Dividend Yield

Profitability & Returns

ROCE

-28.02%

ROE

-49.35%

ROA

-17.62%

Profit Margin

-27.32%

Op Margin

-29.78%

EPS (Latest Qtr)

$-3.25

EPS (TTM)

$-13.48

Balance Sheet & Liquidity

Debt/Equity

0.64

Quick Ratio

2.96

Current Ratio

3.50

Debt

$347.31M

Total Assets

$1.26B

Current Assets

$1.25B

Working Capital

$935.48M

Ownership

Promoter Holding

5.68%

Chg in Prom Hold

FII / Inst Holding

106.22%

Chg in FII Hold

Financial Snapshot

Enterprise Value

$11.00B

Total Revenue (TTM)

$1.13B

EBITDA

$-312.00M

Free Cash Flow

$-156.40M

Operating Cash Flow

$-268.10M

Shares Outstanding

23.06M

Gross Margin

93.07%

Payout Ratio

0.00%

Growth (CAGR)

Revenue 5Y

Profit 5Y

0.80%

Revenue (YoY)

126.80%

Earnings (YoY)

PROS

In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	MDGL Madrigal Pharmaceuticals, Inc. R2K	497.27	-	$11.46B	-	-28.02%	-49.35%	-	0.80%
2	LLY Eli Lilly and Company SPX	1,105.00	39.21	$985.37B	0.63%	38.44%	107.46%	31.69%	48.96%
3	JNJ Johnson & Johnson SPX	225.33	26.11	$542.42B	2.38%	23.13%	26.42%	5.60%	14.32%
4	UNH UnitedHealth Group Incorporated SPX	380.31	28.66	$345.38B	2.32%	9.60%	12.18%	11.35%	-15.69%
5	MRK Merck & Co., Inc. SPX	118.72	33.44	$293.22B	2.86%	20.66%	18.94%	3.12%	7.93%
6	TMO Thermo Fisher Scientific Inc. SPX	492.51	27.11	$183.03B	0.38%	9.17%	13.52%	-0.27%	-1.19%
7	AMGN Amgen Inc. NDXSPX	336.79	23.42	$181.77B	2.99%	18.02%	101.32%	11.77%	5.58%
8	GILD Gilead Sciences, Inc. NDXSPX	134.43	18.29	$166.90B	2.44%	22.92%	43.36%	2.57%	22.83%
9	ISRG Intuitive Surgical, Inc. NDXSPXAI	424.64	51.53	$150.39B	-	15.96%	17.23%	17.39%	29.26%

Quarterly Results

Figures in USD.

Metric	Dec 2015	Mar 2016	Jun 2016	Sep 2016	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	0	14.64M	-	137.25M	212.80M	287.27M	321.08M	311.34M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4.51M	9.06M	18.12M	24.45M	26.85M
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	132.74M	203.74M	269.15M	296.63M	284.49M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	212.05M	250.94M	383.12M	356.24M	377.21M
Operating Income	-10.38M	-738.00K	-2.64M	-14.09M	-6.08M	-8.44M	-8.64M	-8.91M	-7.07M	-7.83M	-11.33M	-14.45M	-18.12M	-22.70M	-24.20M	-29.95M	-38.01M	-50.33M	-58.79M	-59.55M	-52.98M	-61.74M	-63.16M	-64.60M	-57.59M	-70.27M	-80.41M	-85.30M	-78.34M	-86.45M	-98.53M	-117.18M	-152.04M	-162.54M	-	-79.31M	-47.20M	-113.97M	-59.61M	-92.72M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-69.56M	-38.64M	-106.38M	-49.89M	-86.19M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3.30M	3.26M	7.45M	8.30M	7.82M
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-73.24M	-42.28M	-114.19M	-58.58M	-94.39M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-	-	-	-	-6.00M	-8.35M	-8.36M	-8.45M	-6.36M	-6.46M	-8.51M	-11.47M	-15.08M	-19.70M	-21.43M	-27.74M	-36.13M	-49.02M	-57.96M	-59.12M	-52.55M	-61.65M	-63.10M	-64.55M	-57.52M	-70.73M	-81.20M	-85.91M	-76.90M	-85.80M	-98.74M	-112.19M	-147.54M	-151.97M	-	-73.24M	-42.28M	-114.19M	-58.58M	-94.39M
Diluted EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-3.32	-3.72	-3.79	-3.78	-3.36	-4.14	-4.75	-4.98	-4.23	-4.69	-5.34	-5.68	-7.38	-7.10	-	-2.61	-1.90	-5.08	-2.57	-3.25

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	180.13M	958.40M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	6.23M	56.15M
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	173.90M	902.25M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	293.57M	380.50M	671.77M	1.20B
Operating Income	79.30M	-36.90M	-45.43M	-60.94M	-87.56M	-83.95M	-3.23M	-25.22M	-32.06M	-40.68M	-94.97M	-206.67M	-	-293.57M	-380.50M	-497.88M	-300.10M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-290.92M	-360.39M	-450.12M	-264.47M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	3.96M	12.71M	14.67M	22.31M
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-295.35M	-373.63M	-465.89M	-288.28M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-	-	-	-	-	-	-	-26.39M	-31.15M	-32.81M	-83.95M	-202.24M	-	-295.35M	-373.63M	-465.89M	-288.28M
Diluted EPS	2.32	-0.93	-1.00	-	-	-	-	-	-	-	-	-13.09	-	-17.23	-19.99	-21.90	-12.85

Compounded Sales Growth

5 Years:	-
1 Year:	126.80%

Compounded Profit Growth

5 Years:	0.80%
1 Year:	-

Stock Price Performance

1 Year:	+80.65%
6 Months:	-16.01%
3 Months:	+15.11%
1 Month:	-4.11%

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	54.07M	42.32M	103.02M	95.20M	100.67M	363.58K	41.21M	192.31M	485.43M	442.06M	287.00M	-	362.57M	640.55M	1.04B	1.26B
Current Assets	-	-	-	-	-	-	-	-	-	-	-	-	-	-	361.37M	637.28M	1.03B	1.25B
Cash & Equivalents	52.05M	44.16M	31.31M	30.07M	81.51M	48.49M	148.07K	306.00K	19.14M	148.63M	57.38M	46.70M	54.00M	-	331.55M	99.92M	100.02M	198.69M
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	34.07M	74.84M
Receivables	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	53.82M	134.48M
Total Liabilities	-	-	30.59M	27.55M	27.95M	46.11M	35.54M	49.28M	4.80M	10.05M	8.44M	25.49M	47.02M	-	165.18M	235.21M	287.86M	656.90M
Current Liabilities	-	-	16.74M	15.15M	23.49M	32.21M	30.89M	49.28M	4.80M	10.05M	8.44M	25.13M	46.56M	-	115.89M	118.55M	169.28M	310.29M
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	49.29M	115.48M	117.57M	339.88M
Total Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	49.89M	117.19M	119.57M	347.63M
Total Equity	-58.79M	24.91M	23.48M	14.77M	75.07M	49.09M	-42.07M	-48.91M	36.41M	182.26M	476.98M	416.56M	239.97M	-	197.39M	405.33M	754.38M	602.69M
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	-	-	-	18.10M	19.88M	22.00M	22.84M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-	-	-	-	-	-	-	-17.61M	-22.32M	-25.51M	-41.62M	-157.56M	-183.92M	-224.86M	-324.23M	-455.57M	-189.55M
Investing Cash Flow	-	-	-	-	-	-	-	21.99M	-22.01M	-380.08M	30.71M	159.78M	-5.05M	206.69M	-502.52M	-274.39M	32.32M
Financing Cash Flow	-	-	-	-	-	-	-	14.45M	173.81M	314.33M	235.00K	5.09M	171.24M	313.45M	595.12M	735.06M	255.98M
Capital Expenditure	-454.00K	-136.00K	-690.00K	-505.00K	-769.00K	-144.00K	-58.00K	-3.00K	-125.00K	-22.00K	-172.00K	-334.00K	-209.00K	-217.00K	-1.48M	-6.46M	-3.47M
Free Cash Flow	-	-	-	-	-	-	-	-17.61M	-22.44M	-25.53M	-41.80M	-157.90M	-184.13M	-225.07M	-325.71M	-462.03M	-193.02M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-	-	-	-	295.28M	-231.63M	5.10M	98.75M
Share Buybacks	-	-	-	32.00K	-	-	-	-	-	-	-	-	-	-	-	-	-

Ratios (Annual)

Figures in %.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	96.5%	94.1%
Operating Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-276.4%	-31.3%
Net Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-258.6%	-30.1%
ROE %	-	-	-	-	-	-	-	-72.5%	-17.1%	-6.9%	-20.2%	-84.3%	-	-149.6%	-92.2%	-61.8%	-47.8%
ROCE %	-	-98.8%	-167.2%	-76.6%	-139.0%	-120.3%	6.6%	-69.3%	-17.6%	-8.5%	-22.8%	-86.0%	-	-119.0%	-72.9%	-57.0%	-31.6%

Shareholding Pattern

Insiders

5.68%

Institutions

106.22%

Public Float

112.61%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Baker Bros. Advisors, LP	9.29%	2.14M	$1.07B
2	Janus Henderson Group PLC	8.76%	2.02M	$1.00B
3	RTW Investments LP	8.65%	1.99M	$991.40M
4	Avoro Capital Advisors LLC	7.89%	1.82M	$904.13M
5	Blackrock Inc.	6.77%	1.56M	$775.72M
6	PAULSON & CO. INC.	6.04%	1.39M	$692.29M
7	Vanguard Portfolio Management LLC	3.65%	841.14K	$418.28M
8	Vanguard Capital Management LLC	3.59%	827.14K	$411.31M
9	Wellington Management Group, LLP	3.01%	694.96K	$345.58M
10	State Street Corporation	2.64%	609.52K	$303.10M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for MDGL

No recent headlines available.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

Sector	Healthcare
Industry	Biotechnology
Headquarters	United States
Employees	915
Website	https://www.madrigalpharma.com

Madrigal Pharmaceuticals, Inc. MDGL R2K

Market & Price

Valuation

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Growth (CAGR)

PROS

CONS

Price Chart

Technical Trend

Fundamental Growth

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Compounded Sales Growth

Compounded Profit Growth

Stock Price Performance

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

Explore More